CJC-1295 Ipamorelin Compound

the literature // sourced

CJC-1295 Ipamorelin References

Every figure on this site traces to one of these. DOIs and PubMed links included.

Back to the researchRead the effects

Core literature

The studies behind the CJC-1295 Ipamorelin claims on this site, numbered as cited. Single-component pharmacology, the synergy evidence, the class safety synthesis, and the read-across comparator data — each line carries its DOI and PubMed identifier. Where a finding is extrapolated rather than measured for the blend, the body pages say so; these are the sources that are measured.

Most recent additions

The freshest entries in the record (2025–2026): the tesamorelin meta-analysis [7], a gerontology peptide review grouping ipamorelin among non-approved peptides lacking long-term safety data, a 2026 musculoskeletal peptide safety/efficacy appraisal, and a 2025 nano-LC-MS method for detecting GHRH analogues in urine (anti-doping context). These extend, but do not change, the central picture: strong single-component pharmacology, no controlled trial of the fixed combination.

  1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. ↗
  2. Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. ↗
  3. Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. ↗
  4. Cunha SR, et al. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-82. ↗
  5. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. ↗
  6. Sigalos JT, et al. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. ↗
  8. Farhy LS, et al. Deterministic construct of amplifying actions of ghrelin on pulsatile growth hormone secretion. Am J Physiol Regul Integr Comp Physiol. 2005;288(6):R1649-63. ↗
  9. Devesa J, et al. The Complex World of Regulation of Pituitary Growth Hormone Secretion: The Role of Ghrelin, Klotho, and Nesfatins in It. Front Endocrinol. 2021;12:636403. ↗
  10. Norman C, et al. Estradiol regulates GH-releasing peptide's interactions with GH-releasing hormone and somatostatin in postmenopausal women. Eur J Endocrinol. 2014;170:121-9. ↗
  11. Fraser GL, et al. Effect of the ghrelin receptor agonist TZP-101 on colonic transit in a rat model of postoperative ileus. Eur J Pharmacol. 2009;604:132-7. ↗
  12. Venkova K, et al. Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus. Dig Dis Sci. 2007;52:2241-8. ↗